Kosmopoulos Marinos, Bartos Jason A, Kalra Rajat, Goslar Tomaz, Carlson Claire, Shaffer Andrew, John Ranjit, Kelly Rose, Raveendran Ganesh, Brunsvold Melissa, Chipman Jeffrey, Beilman Gregory, Yannopoulos Demetris
Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA.
Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA; Department of Intensive Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Slovenia.
Hellenic J Cardiol. 2021 Jan-Feb;62(1):38-45. doi: 10.1016/j.hjc.2020.04.013. Epub 2020 May 7.
To investigate the baseline risk of patients treated with Extracorporeal Cardiopulmonary Membrane Oxygenation (ECMO) in relation to cannulation strategy and indication for ECMO as well as the relation of cannulation strategy with survival and secondary hospitalization outcomes.
Severity of illness and predicted mortality risk were assessed in 317 patients. Central cannulation was used in 52 patients unable to wean off cardiopulmonary bypass after cardiac surgery. Peripheral cannulation was used in 179 patients for extracorporeal cardiopulmonary resuscitation (eCPR) and in 86 patients who received ECMO for refractory cardiogenic shock (RCS).
Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were significantly worse (P < 0.01) for peripheral ECMO eCPR (23.2) vs central ECMO (14.6) and vs peripheral ECMO for RCS (18.9). Survival After Venoarterial ECMO (SAVE) scores were significantly worse for peripheral ECMO for eCPR (-7.85) and RCS (-10.38) vs central ECMO (-3.97), and P < 0.01. Peripherally cannulated patients had significantly worse renal function. No significant difference existed for survival to discharge (peripheral ECMO for eCPR, 31%; central ECMO, 44%; peripheral ECMO for refractory cardiac shock, 39.5%; and P = 0.176), although centrally cannulated patients had significantly longer treatment durations compared with peripheral ECMO for eCPR.
Peripherally cannulated patients with eCPR had significantly worse APACHE II and SAVE scores compared to peripherally cannulated RCS or patients with central ECMO, despite having similar mortality.
探讨接受体外膜肺氧合(ECMO)治疗的患者的基线风险与插管策略、ECMO适应症的关系,以及插管策略与生存和二次住院结局的关系。
对317例患者的疾病严重程度和预测死亡风险进行评估。52例心脏手术后无法脱离体外循环的患者采用中心插管。179例患者采用外周插管进行体外心肺复苏(eCPR),86例因难治性心源性休克(RCS)接受ECMO治疗的患者采用外周插管。
外周ECMO eCPR组的急性生理与慢性健康状况评估II(APACHE II)评分(23.2)显著高于中心ECMO组(14.6)和外周ECMO治疗RCS组(18.9)(P<0.01)。外周ECMO治疗eCPR组(-7.85)和RCS组(-10.38)的静脉-动脉ECMO后生存(SAVE)评分显著高于中心ECMO组(-3.97),P<0.01。外周插管患者的肾功能明显较差。出院生存率无显著差异(外周ECMO治疗eCPR组为31%;中心ECMO组为44%;外周ECMO治疗难治性心源性休克组为39.5%;P=0.176),尽管中心插管患者的治疗时间明显长于外周ECMO治疗eCPR组。
与外周插管治疗RCS的患者或接受中心ECMO治疗的患者相比,接受eCPR的外周插管患者的APACHE II和SAVE评分显著更差,尽管死亡率相似。